162. Pemphigoid Clinical trials / Disease details
Clinical trials : 83 / Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03926377 (ClinicalTrials.gov) | April 2019 | 15/4/2019 | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid | Osteoporosis;Bullous Pemphigoid | Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate | Centre Hospitalier Universitaire, Amiens | University Hospital, Rouen | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 4 | NULL |
| 2 | NCT03286582 (ClinicalTrials.gov) | September 5, 2017 | 14/9/2017 | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid | A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid | Bullous Pemphigoid | Drug: AC-203 1% Topical Ointment;Drug: Clobetasol 0.05% Topical Ointment | TWi Biotechnology, Inc. | NULL | Terminated | 20 Years | 90 Years | All | 10 | Phase 2 | Taiwan |
| 3 | NCT02360202 (ClinicalTrials.gov) | April 2015 | 7/1/2015 | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid | Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Procedure: Impedance analysis;Drug: Clobetasol Propionate cream treatment | University Hospital, Rouen | Société de Dermatologie Française | Recruiting | 18 Years | N/A | All | 35 | Phase 4 | France |
| 4 | NCT02313870 (ClinicalTrials.gov) | January 22, 2008 | 8/12/2014 | Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid | Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid | Bullous Pemphigoid | Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone | University Hospital, Montpellier | NULL | Completed | 18 Years | N/A | All | 322 | Phase 3 | France |